title: Ventricular tachyarrhythmias in a canine model of LQT3: arrhythmogenic effects of sympathetic activity and therapeutic effects of mexiletine.
abstract: The ventricular tachyarrhythmias associated with the LQT3 syndrome are typically bradycardia-dependent. However, some episodes can be associated with exercise or emotional stress, suggesting a different arrhythmogenic mechanism when sympathetic activity predominates. This study examined the potential arrhythmogenic mechanisms during periods of autonomically mediated transient heart rate acceleration in a canine anthopleurin-A model of LQT3 syndrome. Using plunge needle electrodes, transmural unipolar electrograms of the left ventricle were recorded from endocardial (Endo), mid-myocardial (Mid) and epicardial (Epi) sites. The activation-recovery interval (ARI) was measured to estimate local refractoriness. The cardiac cycle length was gradually shortened by cessation of vagal stimulation (vagal stimulation protocol (VSP)), and intramural electrograms and onset mode of ventricular tachyarrhythmias were analyzed in 7 experiments. The VSP was performed 8 times before and 5 times after administration of mexiletine in each experiment. Before mexiletine, vagal stimulation slowed the heart rate and created large transmural ARI dispersion because of a greater ARI prolongation at Mid rather than Epi/Endo sites. After cessation of vagal stimulation, unipolar electrograms started to show ARI alternans and ventricular premature beats developed sporadically. Sustained ventricular tachyarrhythmias were induced in 12 of the 56 trials of the VSP. Initiation of ventricular tachyarrhythmias was associated with delayed conduction at Mid/Endo sites. Mexiletine attenuated transmural ARI dispersion, and neither ARI alternans nor ventricular tachyarrhythmias was observed during all 35 trials of the VSP after mexiletine administration. Heart rate acceleration induced by an abrupt shift to a state of predominant sympathetic activity enhances arrhythmias in this LQT3 model. Mexiletine homogenizes ventricular repolarization, suppresses premature complexes and was antiarrhythmic during ventricular tachyarrhythmias induced by the VSP.
authors.affiliation: School of Health Science, Niigata University School of Medicine, Japan. masaomi@clg.niigata-u.ac.jp
authors.forename: Masaomi
authors.initials: M
authors.lastname: Chinushi
authors.forename: Minoru
authors.initials: M
authors.lastname: Tagawa
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Sugiura
authors.forename: Satoru
authors.initials: S
authors.lastname: Komura
authors.forename: Yukio
authors.initials: Y
authors.lastname: Hosaka
authors.forename: Takashi
authors.initials: T
authors.lastname: Washizuka
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Aizawa
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004285:Dogs; D004562:Electrocardiography; D006339:Heart Rate; D008133:Long QT Syndrome / Q000150:complications* / Q000503:physiopathology; D008801:Mexiletine / Q000494:pharmacology*; D023421:Models, Animal; D013564:Sympathetic Nervous System; D017180:Tachycardia, Ventricular / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D014630:Vagus Nerve / Q000503:physiopathology
chemical_list: D000889:Anti-Arrhythmia Agents; D008801:Mexiletine